Liberum Capital Reaffirms Hold Rating for Genus (GNS)
A number of other research firms have also commented on GNS. Kepler Capital Markets assumed coverage on shares of Genus in a research report on Tuesday, November 7th. They issued a hold rating and a GBX 2,353 ($33.04) price target on the stock. Peel Hunt reissued a buy rating and issued a GBX 2,600 ($36.51) price target on shares of Genus in a research report on Monday, October 9th. Finally, N+1 Singer raised shares of Genus to a buy rating and lifted their price target for the company from GBX 1,844 ($25.90) to GBX 2,485 ($34.90) in a research report on Monday, October 30th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of Hold and an average price target of GBX 2,270.60 ($31.89).
Genus (LON:GNS) opened at GBX 2,372 ($33.31) on Monday. Genus has a 52-week low of GBX 1,652 ($23.20) and a 52-week high of GBX 2,597 ($36.47). The company has a market cap of $1,460.00 and a P/E ratio of 4,475.47.
Genus plc is an animal genetics company, which provides farmers with genetics that enable them to produce animal protein, in the form of meat and milk. The Company’s segments include Genus PIC, Genus ABS, Genus Asia, and Research and Development. The Genus PIC segment is engaged in porcine sales business, excluding Asia, and serves porcine customers in North America, Latin America and Europe.
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.